UNSPSC 51334404: Citatepine

This classification denotes a dopamine antagonist with the molecular formula C20H18N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92S48G7U0W, chemically known as 2,3,4,5-tetrahydro-3-methyl-1h-dibenzo(2,3:6,7)thiepino(4,5-d)azepine-7-carbonitrile. but generally known as citatepine, which bears US NIH Compound Identifier 193991. European Medicines Agency schedules Citatepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07486MIG.

UNSPSC 51334404 Citatepine, a Commodity-level code, represents pharmaceutical products procured by state and local health agencies, county health departments, and multistate cooperative purchasing alliances. State and local governments under this code buy generic pharmaceuticals, naloxone and opioid-reversal systems, over-the-counter (OTC) products, and specialty therapeutic medications distributed through authorized drug wholesalers and direct-to-manufacturer channels to support community health initiatives, employee health plans, and Medicaid or state health benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing consortiums (Minnesota Multistate Cooperative Purchasing Alliance operating across Minnesota and Oregon). The mix reflects both direct county procurement for community health delivery and state-level aggregated purchasing that serves multiple participating jurisdictions and authorized wholesale distribution networks.

Recent activity clusters in Florida, Texas, and the Minnesota–Oregon cooperative region. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market-intelligence phase preceding formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and meet cGMP and Drug Supply Chain Security Act certification standards. Contract awards are multi-award structures based on therapeutic need, product availability, and patient safety, with pricing weighted at 75 percent of evaluation.